Trial Profile
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CANTATA-D2
- Sponsors Janssen Research & Development
- 17 Apr 2019 Results assessing the effect of the SGLT2 inhibitor canagliflozin on biomarkers for progression of diabetic kidney disease published in the Diabetologia
- 08 Jan 2018 Results (n=2536) of pooled analysis of NCT01106625, NCT01106677, NCT01137812 and NCT02025907 trials assessing effect of Canagliflozin on health related quality of life and patients' satisfaction published in The Patient - Patient-Centered Outcomes Research
- 01 Dec 2016 Pooled analysis of 7 studies including this one and results of substudy of the CANVAS trial (n=432) were published in the Diabetes Therapy.